Figure 6 in Inflammation reduction potential of nanostructured lipid carriers encapsulated with rat's bone marrow cells' lysate

Figure 6. Percentage inhibition of inflammation at a time interval (hr) in carrageenan-induced rat's hind paw oedema model. The effect of different treatment groups, i.e., normal (N), normal rat paw injected with normal saline (N-NS), carrageenan injected group (C), carrageenan injected with normal saline group (C-NS), carrageenan injected with diclofenac sodium group (C-I-DFS), carrageenan injected with nanostructured lipid carriers group (C-I-NLC), carrageenan injected with bone marrow-derived mesenchymal stromal cells (BMSCs) lysate group (C-I-BMSCs-L) and Carrageenan injected with NLC loaded BMSCs lysate group (C-I-NLC-BMSCs-L); on hind paw oedema at different hours (0, 1 2, 3, 6 & 24 hours). Where; the* sign shows significance between normal and carrageenan-induced treated groups while α and ss sign shows significance between carrageenan injected and carrageenaninduced treatment groups. Where; ns is non-significant, ** & ss denotes P<0.001, *** & αss denotes P<0.0001.